# EDGAR Filing Document

**Accession Number:** 0001837821
**File Stem:** 0001213900-25-084742
**Filing Date:** 2025-9
**Character Count:** 2414
**Document Hash:** 23c87f2be150c48697bd1de1c59921a6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-084742.hdr.sgml**: 20251205

**ACCESSION NUMBER**: 0001213900-25-084742

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250905

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jin Medical International Ltd.
- **CENTRAL INDEX KEY:** 0001837821
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** NO. 33 LINGXIANG ROAD, WUJIN DISTRICT
- **STREET 2:** CHANGZHOU CITY
- **CITY:** JIANGSU PROVINCE
- **STATE:** F4
- **ZIP:** 213149
- **BUSINESS PHONE:** (86)51989607972

**MAIL ADDRESS:**
- **STREET 1:** NO. 33 LINGXIANG ROAD, WUJIN DISTRICT
- **STREET 2:** CHANGZHOU CITY
- **CITY:** JIANGSU PROVINCE
- **STATE:** F4
- **ZIP:** 213149

**Jin Medical International Ltd.**

No. 33 Lingxiang Road, Wujin District

Changzhou City, Jiangsu Province

People's Republic of China

**September 5, 2025**

**VIA EDGAR**

Securities and Exchange Commission

Division of Corporate Finance

100 F Street, NE

Washington, D.C. 20549

Attn: Ms. Jane Park

---

| | |
|:---|:---|
| **Re:** | **Jin Medical International Ltd.**<br> **Registration Statement on Form F-3**<br> **File No. 333-288314** |

---

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended, Jin Medical International Ltd. hereby requests the United States Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form F-3 to become effective on September 9, 2025, at 9:00 a.m. Eastern Time, or as soon thereafter as practicable.

Please feel free to direct any questions or comments concerning this request to our U.S. legal counsel, Ms. Huan Lou of McCarter & English, LLP by telephone at +1 (212)-609-6921 or via e-mail at <u>hlou@mccarter.com</u>.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| For and on behalf of<br> Jin Medical International Ltd. | For and on behalf of<br> Jin Medical International Ltd. |
| */s/ Erqi Wang* | */s/ Erqi Wang* |
| Name: | Erqi Wang |
| Title: | Chief Executive Officer |

---